Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 8, 2013

Leica Biosystems Nabs Kreatech

  • Leica Biosystems has acquired molecular diagnostics firm Kreatech Diagnostics, a provider of DNA fluorescent in situ hybridization (FISH) probes and target-labeling reagents for microarrays. Leica Biosystems focuses on workflow solutions and automation with the aim of advancing cancer diagnostics.

    Kreatech will join Leica Biosystems' Advanced Staining business unit based in Newcastle-upon-Tyne, U.K. The combined business will develop targeted biomarker menus for Leica's instrument platforms. Financial terms of the deal were not disclosed.

    "This will allow Leica Biosystems to better serve our cytogenetics and anatomic pathology customers," said Matthias G. Weber, M.D., president of Leica Biosystems. "It will also enable us to actively support the future development of personalized medicine by research and drug development companies."

    Kees Moonen, CEO of Kreatech Diagnostics, said he believes "Leica will bring global brand recognition, worldwide commercial reach, extensive cytogenetics and histology portfolios, and the automation of diagnostic tests on well-established systems" to Kreatech.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »